Erispirus tabs 80mg #30

Erispirus instruction for use

Reed more and buy Erispirus on this page

Composition

1 tablet contains: active ingredient: fenspiride hydrochloride - 80.0 mg;
auxiliary substances: core: silicon dioxide colloidal anhydrous 0.5 mg; magnesium stearate 2.2 mg; hypromellose K100 M - 10.0 mg; Povidone K-30 - 12.8 mg; hypromellose E15 - 30.0 mg; hypromellose K15 M - 60.0 mg; calcium hydrophosphate dihydrate - 104.5 mg; Sheath: Macrogol 6000 - 0.3 mg; glycerin - 0.3 mg; magnesium stearate - 0.3 mg; titanium dioxide - 0.8 mg; hypromellose E5 - 4.4 mg.
Description: round, biconvex tablets, film-coated, from white to white with a cream color shade.
Pharmacotherapeutic group:
anti-inflammatory anti-bronchoconstrictive agent.
ATX code: R03DX03.

Pharmacological properties

Pharmacodynamics

Anti-inflammatory and anti-bronchoconstrictive activity of fenspiride is caused by a decrease in the production of a number of biologically active substances (cytokines, especially tumor necrosis factor α (TNF-α), arachidonic acid derivatives, free radicals) that play an important role in the development of inflammation and bronchospasm.
Inhibition of fenspiride metabolism of arachidonic acid is potentiated by its H1-antihistamine action, t. histamine stimulates the metabolism of arachidonic acid with the formation of prostaglandins and leukotrienes. Fenspiride blocks α-adrenoreceptors, stimulation of which is accompanied by an increase in the secretion of bronchial glands.
Thus, fenspiride reduces the effect of a number of factors that contribute to the hypersecretion of pro-inflammatory factors, the development of inflammation and bronchial obstruction.
Fenspiride also has an antispasmodic effect.

Pharmacokinetics

After oral administration, the maximum concentration in the blood plasma (Cmax) is achieved after 2.3 ± 2.5 hours (0.5 to 8 hours).
It is excreted mainly by the kidneys, the elimination half-life (T1 / 2) is 12 hours.

Indications for use

Diseases of the upper and lower respiratory tract:
• Rhinopharyngitis and laryngitis;
• tracheobronchitis;
• bronchitis;
• bronchial asthma in complex therapy;
• respiratory symptoms (cough, hoarseness, throat swelling) with measles, pertussis, influenza;
• for infectious diseases of the respiratory tract accompanied by cough, when standard antibiotic therapy is indicated;
• sinusitis and otitis of various etiologies.

Contraindications for Erispirus

• hypersensitivity to fenspiride and other components of Erispirus;
• pregnancy;
• Lactation period;
• Children under 18 years.
With caution, bacterial and fungal infections, diabetes mellitus, concurrent use of sedatives.

Application in pregnancy and during breastfeeding

Data on the use of Erispirus in pregnant women are absent or limited.
Taking the drug during pregnancy is not recommended.
Therapy with fenspiride is not a reason for interrupting the pregnancy that has occurred.
Clinical data on the fetotoxic effect of fenspiride or its ability to cause malformations during admission during pregnancy are absent.
It is not known whether fenspiride penetrates into breast milk. If it is necessary to use Erispirus during breastfeeding, it is necessary to resolve the issue of stopping breastfeeding.

Dosing and Administration

Inside. Before eating.
Adults over the age of 18:
1 tablet 2 times a day (160 mg fenspiride) (morning and evening).
In the case of acute conditions, it is recommended to take 1 tablet three times a day (240 mg fenspiride).
The maximum daily dose is 240 mg.
The duration of therapy is determined by the attending physician.

Side effects of Erispirus

According to the World Health Organization (WHO), adverse reactions are classified according to their frequency of development as follows: very often (> 1/10), often (> 1/100, <1/10), infrequently (> 1/1000, < 1/100), rarely (> 1/10000, <1/1000) and very rarely (<1/10000); frequency is unknown - according to available data, it was not possible to establish the frequency of occurrence.
From the nervous system:
rarely: drowsiness;
frequency unknown: dizziness.
From the cardiovascular system:
rarely: sinus tachycardia, the severity of which decreases with a decrease in the dose of Erispirus;
the frequency is unknown: a palpitations, a decrease in blood pressure, possibly associated with tachycardia.
From the gastrointestinal tract:
often: gastrointestinal disorders, nausea, pain in the epigastric region;
frequency unknown: diarrhea, vomiting.
From the skin and subcutaneous tissues:
rarely: erythema, rash, hives, angioedema, fixed erythema pigmentosa;
frequency is unknown: itching, toxic epidermal necrolysis, Stevens-Johnson syndrome.
Other:
frequency unknown: asthenia, increased fatigue.

Overdose

If an overdose of Erispirus should immediately seek medical help.
Symptoms: drowsiness or agitation, nausea, vomiting, sinus tachycardia.
Treatment: symptomatic therapy, gastric lavage, ECG monitoring. Maintaining important body functions.

Interaction with other drugs

Because of the possible increase in the sedative effect when taking blockers of histamine H1 receptors, the use of the drug in combination with drugs with a sedative effect is not recommended.
It is not recommended simultaneous use of Erispirus with alcohol.

special instructions for Erispirus

For the treatment of children and adolescents under the age of 18, it is recommended to use fenspiride syrup.
In the event of infections of the respiratory system caused by bacteria or fungi, fenspiride is recommended to be prescribed only in combination with antibacterial and antifungal therapy.
Special precautions for the destruction of unused medicinal product
There is no need for special precautions when destroying an unused preparation of Erispirus.

Influence on ability to drive vehicles, mechanisms

Studies to study the effect of Erispirus on the ability to drive vehicles and work with mechanisms have not been carried out. Patients should be aware of the possible development of drowsiness when taking Erispirus, especially at the beginning of therapy or in combination with the intake of alcohol. Care must be taken when working with vehicles, mechanisms.

Form of issue

Tablets of prolonged action, film-coated, 80 mg
For 10 or 15 tablets of prolonged action, film-coated, in PVC / Al blisters.
2 blisters for 10 tablets or 1, 2, 3, 4 blisters of 15 tablets per pack of cardboard along with instructions for use.

Storage conditions

Store at a temperature not exceeding 25 ° C.
Keep out of the reach of children.
Shelf life - 2 years.
Do not use the product after the expiry date printed on the package.

Leave conditions

You don't need a prescription to buy Erispirus.